# Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

> **NCT06857747** · NA · UNKNOWN · sponsor: **QIAO LI** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Vinorelbine
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT06857747
- **Lead sponsor:** QIAO LI
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2025-03-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857747, "Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06857747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*